Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.

摘要: Background: Livedoid vasculopathy is a recurrent thrombo-occlusive of cutaneous blood vessels and its standard or first-line therapy still controversial. Besides hypercoagulability, inflammatory factors may also play secondary role in the pathogenesis this disease. Monotherapy thrombolytics cannot achieve satisfactory results because concomitant inflammation.Objective: This pilot study aimed to determine efficacy an anti-TNF-alpha agent patients with refractory livedoid vasculopathy.Methods: We studied five who were resistant steroids, antiplatelets, danazol therapy, treated etanercept 25-50 mg once week for 12 consecutive weeks. assessed clinical characteristics, laboratory findings, etanercept's on skin lesions, pain, quality life.Results: Etanercept resulted fast relief pain mean time 2 The median duration disappearance erythema ulcer healing was 8.8 weeks 10.6 weeks, respectively. There reduction by 34.3% after treatment. Disease severity life significantly improved.Conclusions: In patients, efficient lesions improvement life, especially rapid pain.